SCHEMBL117727

SCHEMBL117727

CSC1C(=O)Nc2c(Cl)cccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNB4 O00305 2/20 0.40
▸ CACNA1A O00555 2/20 0.40
▸ CACNA1G O43497 2/20 0.40
▸ CACNG3 O60359 2/20 0.40
▸ CACNA1F O60840 2/20 0.40
▸ CACNA1H O95180 2/20 0.40
▸ CACNB3 P54284 2/20 0.40
▸ CACNA2D1 P54289 2/20 0.40
▸ CACNG7 P62955 2/20 0.40
▸ CACNA1B Q00975 2/20 0.40
▸ CACNA1D Q01668 2/20 0.40
▸ CACNB1 Q02641 2/20 0.40
▸ CACNG1 Q06432 2/20 0.40
▸ CACNB2 Q08289 2/20 0.40
▸ CACNA1S Q13698 2/20 0.40
▸ CACNA1C Q13936 2/20 0.40
▸ CACNA1E Q15878 2/20 0.40
▸ CACNA2D4 Q7Z3S7 2/20 0.40
▸ CACNA2D3 Q8IZS8 2/20 0.40
▸ CACNG8 Q8WXS5 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15966870 0.87 AHR (0.62) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL10712822 0.86 ALDH1A1 (0.40) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL11093677 0.86 CACNB4 (0.36) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL11097244 0.84 CACNA1B (0.37) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL11368672 0.81 DAO (0.40) DAOALDH1A1MAPTCA12CA1
SCHEMBL11094086 0.79 HTR1A (0.34) ALDH1A1CYP2C9CYP2C19
SCHEMBL10713399 0.78 PGR (0.36) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL1321330 0.78 HTR2C (0.46) CACNA1BALDH1A1MAPTCYP2C9HPGD
SCHEMBL24112933 0.77 PGR (0.49) CACNB4CACNA1ACACNA1GCACNG3CACNA1F
SCHEMBL24112226 0.77 PGR (0.49) CACNB4CACNA1ACACNA1GCACNG3CACNA1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242934-B2 Process for the preparation of oxindoles and ortho-substituted anilines and their use as intermediates for syntheses BAYER CROPSCIENCE AG (DE) 2016-01-26 — — US disclosed
EP-2424835-B1 METHOD FOR PRODUCING OXINDOLES AND ORTHO-SUBSTITUTED ANILINES BAYER IP GMBH (DE) 2015-07-01 — — EP disclosed
US-20130281711-A1 PROCESS FOR THE PREPARATION OF OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THEIR USE AS INTERMEDIATES FOR SYNTHESES BAYER CROPSCIENCE AG (DE) 2013-10-24 — — US disclosed
US-8563749-B2 Process for preparing substituted 1,3-dihydro-2H-indol-2-ones BAYER CROPSCIENCE AG (DE) 2013-10-22 — — US disclosed
US-8492590-B2 Process for the preparation of oxindoles and ortho-substituted anilines and their use as intermediates for syntheses BAYER CROPSCIENCE AG (DE) 2013-07-23 — — US disclosed
CN-102985406-A Process for preparing substituted 1,3-dihydro-2h-indol-2-ones BAYER CROPSCIENCE AG 2013-03-20 — — CN disclosed
WO-2012028162-A1 PROCESS FOR PREPARING OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THE USE THEREOF AS INTERMEDIATES FOR SYNTHESES BAYER CROPSCIENCE AG (DE) 2012-03-08 — — WO disclosed
EP-2424835-A1 METHOD FOR PRODUCING OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THE USE THEREOF AS INTERMEDIATE PRODUCTS FOR SYNTHESES Bayer CropScience AG (DE) 2012-03-07 — — EP disclosed
US-20110275832-A1 Process for Preparing Substituted 1,3-dihydro-2H-indol-2-ones BAYER CROPSCIENCE AG (DE) 2011-11-10 — — US disclosed
US-20110118478-A1 PROCESS FOR THE PREPARATION OF OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THEIR USE AS INTERMEDIATES FOR SYNTHESES BAYER CROPSCIENCE AG (DE) 2011-05-19 — — US disclosed
WO-2010127786-A1 METHOD FOR PRODUCING OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THE USE THEREOF AS INTERMEDIATE PRODUCTS FOR SYNTHESES BAYER CROPSCIENCE AG (DE) 2010-11-11 — — WO disclosed
EP-2246326-A1 Method for producing oxindoles and ortho-substituted anilines and their use as intermediate products for syntheses Bayer CropScience AG (DE) 2010-11-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118478-A1 PROCESS FOR THE PREPARATION OF OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THEIR USE AS INTERMEDIATES FOR SYNTHESES TH, OXSR1, AOX1 CACNB4 3953/4885CACNA1A 2765/4885CACNA1G 3890/4885
US-20130281711-A1 PROCESS FOR THE PREPARATION OF OXINDOLES AND ORTHO-SUBSTITUTED ANILINES AND THEIR USE AS INTERMEDIATES FOR SYNTHESES TH, OXSR1, AOX1 CACNB4 3953/4885CACNA1A 2765/4885CACNA1G 3890/4885
US-20110275832-A1 Process for Preparing Substituted 1,3-dihydro-2H-indol-2-ones IDO1, IDO2, TDO2 CACNB4 4582/4885CACNA1A 2930/4885CACNA1G 2412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback